Prostate Cell News 9.39 October 12, 2018 | |
| |
TOP STORYResearchers identified Hsp70 as a co-factor for the N-terminal domain of the androgen receptor (AR) in prostate cancer cells. Hsp70 inhibition using siRNA or small molecules indicated that Hsp70 played an important role in the expression and transactivation of endogenous AR. They showed that Hsp70 was also required for transactivation of AR mutant lacking the ligand binding domain. [Mol Cancer Ther] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Investigators identified microphthalmia-associated transcription factor (MITF) as a prostate tumor suppressor among a subset of transcription factors. They unveiled crystallin alpha B as an unprecedented direct target of the transcription factor that is, at least in part, responsible for its tumor-suppressive activity in prostate cancer. [Cell Death Dis] Full Article AZD5153 Inhibits Prostate Cancer Cell Growth In Vitro and In Vivo AZD5153 inhibited proliferation and survival of established and primary prostate cancer cells. AZD5153 induced apoptosis activation and cell cycle arrest in prostate cancer cells. Pharmacological inhibition or genetic depletion of AKT induced bromodomain-containing protein 4 downregulation, sensitizing AZD5153-induced cytotoxicity in PC-3 cells. [Cell Physiol Biochem] Full Article Transient or stable knockdown of RAD9A in PC-3 cells caused downregulation of AGR2 protein abundance. RAD9A bound specifically to the 5’-untranslated region of AGR2 in PC-3 cells at a partial p53 consensus sequence at position +3136 downstream from the transcription start site. Binding of RAD9A to the p53 consensus sequence was sufficient to drive AGR2 gene transcription. [Carcinogenesis] Abstract Using racially diverse prostate cancer (PCa) cell lines, researchers examined the effects of glucocorticoids on the expression of two stress oncoproteins associated with PCa therapy resistance, clusterin (CLU) and lens epithelium-derived growth factor p75 (LEDGF/p75). They observed that glucocorticoids upregulated LEDGF/p75 and CLU in PCa cells. [Sci Rep] Full Article The authors tested the in vitro cytotoxicity of the metallo-curcumin-conjugated DNA complexes to prostate cancer cells using an MTS assay, which indicated potent growth inhibition of the cells. They studied the cellular uptake of the complexes, revealing that DNA complexes with Cu2+/Ni2+-curcumin exhibited brighter fluorescence than those with Zn2+-curcumin. [Sci Rep] Full Article Genomic Analysis of DNA Repair Genes and Androgen Signaling in Prostate Cancer Scientists indicated that androgen signaling regulated a subset of DNA repair genes that are largely specific to the respective model system and disease state. They identified deleterious mutations in the DNA repair genes RAD50 and CHEK2. They found that inhibition of the DNA repair enzyme MRE11 with the small molecule mirin inhibited androgen-dependent transcription and growth of prostate cancer cells. [BMC Cancer] Full Article Zinc Inhibits Expression of Androgen Receptor to Suppress Growth of Prostate Cancer Cells ZnCl2 suppressed the proliferation of androgen receptor (AR)-retaining prostate cancer (PCa) cells, whereas it did not affect AR-deficient PCa cells. In LNCaP and TRAMP-C2 cells, zinc downregulated the expression of AR in a dose- and time-dependent fashion. Zinc-mediated AR suppression accordingly inhibited the androgen-mediated transactivation and expression of the androgen target, prostate specific antigen. [Int J Mol Sci] Full Article miR-10a Functions as a Tumor Suppressor in Prostate Cancer via Targeting KDM4A Investigators found that miR-10a levels were significantly decreased in prostate cancer (PCa) cell lines in comparison with the normal epithelial cell line RWPE-1. Enhanced expression of miR-10a inhibited cell proliferation and colony forming capability of PCa cells. Cell growth arrest and colony forming capacity inhibition induced by miR-10a overexpression could be reversed by YAP overexpression in PCa cells. [J Cell Biochem] Abstract Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSPI3K Pathway in Prostate Cancer: All Resistant Roads Lead to PI3K The authors discuss the challenges encountered with clinically effective therapies targeting the phosphoinositide 3-kinase (PI3K) pathway in prostate cancer, highlighting the clinical importance of combination therapies. They address how prostate cancer cells utilize the PI3K pathway for the development of resistance to a broad range of anticancer treatments. [BBA Rev Cancer] Abstract Mitochondrial Biology and Prostate Cancer Ethnic Disparity Genetic alterations in mitochondrial DNA are frequent in prostate cancer; therefore, the resulting mitochondrial dysfunction and metabolic dysregulation may contribute to or indicate oncogenesis. In addition, prostate cancer ethnic disparity is influenced by environmental and lifestyle factors, which involves differences in mitochondrial metabolism and retrograde signaling events. [Carcinogenesis] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
SCIENCE NEWSPreclinical Efficacy of Genkyotex’s GKT831 in Prostate Cancer Presented Genkyotex announced the presentation of preclinical data showing that GKT831, the company’s clinical stage NOX1 and NOX4 inhibitor, efficiently targeted cancer associated fibroblasts in prostate cancer and abrogated the pro-tumorigenic influence of the tumor micro-environment. [Press release from Genkyotex discussing research presented at the 25th Meeting of the European Association of Urology, Athens] Press Release | |
| |
INDUSTRY NEWSProgenics Pharmaceuticals, Inc. announced plans to advance I-131 1095, its PSMA-targeted therapeutic, into a Phase II clinical study. [Progenics Pharmaceuticals, Inc.] Press Release Oncology Venture A/S announced that the Danish Medicines Agency has approved an application to broaden the scope of an ongoing Phase II study of LiPlaCis® – an intelligent, target controlled liposome formulation of one of the world’s most widely used chemotherapies, cisplatin. [Oncology Venture] Press Release OncBioMune Pharmaceuticals, Inc. announced that the protocol for the planned Phase II clinical trial of ProscaVax for advanced prostate cancer to be hosted at Urology Clinics of North Texas has been submitted to the U.S. FDA for approval to initiate the study. [OncBioMune Pharmaceuticals, Inc. (GlobeNewswire, Inc.)] Press Release Nymox Pharmaceutical Corporation announced new long-term clinical trial results from the company’s 146 patient Phase IIb NX03-0040 Fexapotide U.S. study for low grade localized prostate cancer. [Nymox Pharmaceutical Corporation] Press Release BioXcel Therapeutics, Inc. announced it has submitted an Investigational New Drug (IND) application to the U.S. FDA to evaluate its lead immuno-oncology candidate, BXCL701, in combination with pembrolizumab as a potential therapy for treatment emergent neuroendocrine prostate cancer. [BioXcel Therapeutics] Press Release CytoDyn unveiled its strategy to complete development of PCaTest, a novel gene-based prognostic test for prostate cancer developed by ProstaGene. [CytoDyn Inc.] Press Release | |
| |
POLICY NEWSArgentina’s Scientists Struggle amid Slipping Peso and Rising Inflation Researchers have struggled under austerity measures adopted by the government in 2014 and intensified in June by a financing agreement that Argentina signed with the International Monetary Fund. [Nature News] Editorial Ghost Authorship Haunts Industry-Funded Clinical Trials An analysis of industry-funded clinical trials has found that drug companies are often heavily involved in research — but are not always transparent about it. [Nature News] Editorial
| |
EVENTSNEW 8th International Oncology Conference: Current Status and Future of Anti-Cancer Targeted Therapies Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame) Group Leader – Biostatistics and Systems Biology in Cancer Research (Oslo University Hospital) Assistant/Associate/Professor – Cancer Biology (University of Cincinnati) Postdoctoral Fellows – Prostate Cancer Research (Weill Cornell Medicine) Postdoctoral Position – Genitourinary Cancers (Columbia University Medical Center) Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities) Research Fellow – Prostate Cancer (Sechenov University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|